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Background and need
 11% of Americans experience daily (chronic) pain
 Opioids frequently prescribed for chronic pain
 Primary care providers 
 account for ~50% of opioid pain medications dispensed
 report concern about opioids and insufficient training 
 16,000 opioid-related overdose deaths in 2013—4 x as many as 
in 1999, continue to increase
 About 2 million people abused or were dependent in 2013
 Existing national guidelines were published in 2010 or earlier 
and do not incorporate new evidence published since 2010
Purpose of a CDC guideline
 Support informed clinical decision making
 Help providers offer safer, more effective care for patients 
with chronic pain
 Help reduce misuse, abuse, and overdose from opioids
 Encourage improved communication between providers and 
patients about the benefits and risks of opioid therapy
 Improve provider confidence regarding when and how to use 
opioids in management of chronic pain
 Benefit patient health
Primary audience
Primary care providers (e.g., family physicians, internists) 
treating patients > 18 years with chronic pain (i.e., lasting > 3 
months or past time of normal tissue healing) in outpatient 
settings outside of active cancer treatment, palliative care, 
and end-of-life care
Systematic Literature Review, CDC Draft Recommendations, Core Expert Group Consultation, CDC Draft Guideline, Core Expert and
Stakeholder Review, Federal Partner Review, Peer Review, Constituent Input (Webinar), CDC Revised Guideline, FRN Public Comment, and BSC 
Engagement.
Overview of the development process
CDC Draft Recommendations
















Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE)
 Standard for guideline development
 Transparent approach for conducting systematic review, 
rating quality of evidence, and determining strength of 
recommendations
 Used by > 100 organizations (including CDC; e.g., ACIP)
 Recommendations based on:
• Quality of evidence
• Balance between benefits and harms
• Values and preferences
• Resource allocation (cost)
Definition of evidence types
 Type 1: Randomized controlled trials or overwhelming 
evidence from clinical studies
 Type 2: Randomized controlled trials with important 
limitations, or exceptionally strong evidence from clinical 
studies
 Type 3: Observational studies or randomized controlled trials 
with notable limitations
 Type 4: Clinical experience and observations, observational 
studies with important limitations, or randomized controlled 
trials with several major limitations
Based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method 
(http://www.gradeworkinggroup.org/)
Category A
 Decision applies to all persons in a specified group
 Most patients should receive recommended course of action
Category B
 Decisions are made on an individual “case by case” basis 
 Choices vary based on patient’s values and preferences, and 
specific clinical situations
 Made when advantages and disadvantages of a clinical 
action are more balanced
Recommendation categories
Organization of Recommendations
The 12 recommendations are grouped into three 
conceptual areas: 
• Determining when to initiate or continue opioids for 
chronic pain 
• Opioid selection, dosage, duration, follow-up, and 
discontinuation
• Assessing risk and addressing harms of opioid use
Determining when to initiate or 
continue opioids for chronic pain
Recommendation One
Nonpharmacologic therapy and nonopioid
pharmacologic therapy are preferred for chronic 
pain. 
Providers should only consider adding opioid 
therapy if expected benefits for both pain and 
function are anticipated to outweigh risks to the 
patient. 
(Recommendation category: A, evidence type: 3)
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation One Rationale
 Insufficient evidence to determine whether pain relief, 
function, or quality of life improves with long-term opioid 
therapy (most RCTs <6 weeks)
 Long-term opioid use for chronic pain is associated with 
serious risks, including abuse, dependence and overdose
 Many non-opioid therapies can improve chronic pain with less 
risk for harm, including exercise therapy, cognitive behavioral 
therapy, non-opioid pharmacologic therapies, and 
multidisciplinary approaches
 When opioids are used, they are more likely to be effective if 
combined with other approaches
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Before starting opioid therapy for chronic pain, 
providers should establish treatment goals with all 
patients, including realistic goals for pain and function. 
Providers should not initiate opioid therapy without 
consideration of how therapy will be discontinued if 
unsuccessful. Providers should continue opioid therapy 
only if there is clinically meaningful improvement in pain 
and function that outweighs risks to patient safety. 
(Recommendation category: A, evidence type: 4) 
Recommendation Two
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
 It is difficult for providers and patients to predict whether 
benefits will outweigh risks of long-term opioid therapy 
• Weak evidence that some patients experience pain relief long-term
• Inconsistent results with currently available risk stratification tools
 Medications should not be continued when harms outweigh 
benefits
 Establishing treatment goals in advance will help providers and 
patients make decisions about continuing or stopping drugs
 Pain relief, function, and quality of life are all important 
Recommendation Two Rationale
Before starting and periodically during opioid therapy, 
providers should discuss with patients known risks and 
realistic benefits of opioid therapy and patient and provider 
responsibilities for managing therapy.
(Recommendation category: A, evidence type: 3)
Recommendation Three
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Three Rationale
 Providers should involve patients in decisions about whether 
to start opioid therapy
 Many patients lack information about opioids
 Essential elements to communicate 
• Realistic expected benefits
• Common and serious harms
• Expectations for both patients and providers to mitigate risks
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Opioid selection, dosage, duration, 
follow-up, and discontinuation
When starting opioid therapy for chronic pain, providers 
should prescribe immediate-release opioids instead of 
extended-release/long-acting (ER/LA) opioids.
(Recommendation category: A, evidence type: 4)
Recommendation Four
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Four Rationale
 Higher overdose risk among patients initiating treatment with 
ER/LA opioids than among those initiating treatment with 
immediate release opioids
 Did not find evidence that continuous, time-scheduled use of 
ER/LA opioids is more effective or safer than intermittent use 
of immediate-release opioids
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
When opioids are started, providers should prescribe the 
lowest effective dosage. 
Providers should use caution when prescribing opioids at any 
dosage, should implement additional precautions when 
increasing dosage to ≥50 morphine milligram equivalents 
(MME)/day, and should generally avoid increasing dosage to 
≥90 MME/day.
(Recommendation category: A, evidence type: 3)
Recommendation Five
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Five Rationale
 Risks for serious harms related to long-term opioid therapy 
increase in a dose-dependent manner
 In a large, national VA sample, 59% of fatal overdose cases had 
dosages above 50 MME and 33% had dosages above 90 MME; 
among cases not experiencing overdose, most (76%) had 
dosages <50 MME; 88% had dosages <90 MME
 Benefits of high-dose opioids for chronic pain not established.
• RCT: no difference in pain, function between more liberal dose 
escalation (average 52 MME at end of study) and maintenance of 
current dosage (average 40 MME at end of study)
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Relationship of prescribed opioid dose in MME 
and overdose risk
Recommendation Six
Long-term opioid use often begins with treatment of acute 
pain. When opioids are used for acute pain, providers should 
prescribe the lowest effective dose and should prescribe no 
greater quantity than needed for the expected duration of 
pain severe enough to require opioids. Three or fewer days 
will usually be sufficient for most nontraumatic pain not 
related to major surgery. 
(Recommendation category: A, evidence type: 4)
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Six Rationale
 Opioid use for acute pain is associated with long-term opioid 
use, and greater amount of early opioid exposure is associated 
with greater risk for long-term use
 More than a few days of exposure significantly increases 
hazards
 Fewer days’ supply minimizes the number of pills available for 
intentional or unintentional diversion
 In most cases of acute pain (e.g., acute back pain) not related 
to major surgery or trauma, pain severe enough to require 
opioids will subside within 3 days
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Providers should evaluate benefits and harms with patients 
within 1 to 4 weeks of starting opioid therapy for chronic pain 
or of dose escalation. Providers should evaluate benefits and 
harms of continued therapy with patients every 3 months or 
more frequently. If benefits do not outweigh harms of 
continued opioid therapy, providers should work with 
patients to reduce opioid dosage and to discontinue opioids.
(Recommendation category: A, evidence type: 4)
Recommendation Seven
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Seven Rationale
 Risks for opioid overdose highest during 1st 2 weeks after 
initiation for ER/LA opioids, within 1st 3 days for methadone
 Patients who do not experience pain relief with opioids at one 
month are unlikely to experience pain relief with opioids at 6 
months
 Continuing opioid therapy for 3 months substantially 
increases risk for opioid use disorder
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Longer durations and higher doses of opioid 






















adjusted OR for opioid use disorder (abuse or dependence) compared with no opioid use
90 or fewer days more than 90 days
Assessing risk and addressing harms 
of opioid use
Recommendation Eight
Prior to starting and periodically during continuation of opioid 
therapy, providers should evaluate risk factors for opioid-related 
harms. Providers should incorporate into the management plan 
strategies to mitigate risk, including considering offering 
naloxone when factors that increase risk for opioid overdose, 
such as history of overdose, history of substance use disorder, or 
higher opioid dosages (>50 MME), are present. 
(Recommendation category: A, evidence type: 4)
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Eight Rationale
 Opioids can worsen central sleep apnea and increase risk for 
respiratory depression and overdose
 Reduced renal or hepatic function can result in  a smaller 
therapeutic window between safe dosages and dosages 
associated with respiratory depression
 Patients with mental health co-morbidities and histories of 
substance use disorder are at higher risk for opioid use 
disorder and overdose
 Community-based naloxone distribution has been associated 
with reduced opioid-related overdose death
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Nine
Providers should review the patient’s history of controlled 
substance prescriptions using state prescription drug monitoring 
program (PDMP) data to determine whether the patient is 
receiving dangerous combinations that put him/her at high risk 
for overdose. Providers should review PDMP data when starting 
opioid therapy for chronic pain and periodically during opioid 
therapy for chronic pain, ranging from every prescription to 
every 3 months 
(Recommendation category: A, evidence type: 4)
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Nine Rationale
 Most fatal overdoses are associated with 
• high total prescribed daily opioid dosages and/or 
• receipt of opioids from multiple prescribers or pharmacies
 Both of these risk factors can be assessed by reviewing PDMP 
data
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Majority of opioid overdose deaths associated 
















Control Patients Patients w/ Fatal Overdose
Multiple sources (> 3
prescribers or pharmacies)
and/or high dosages (>100
MME) of opioids
Fewer sources and lower
dosages of opioids
Baumblatt JAG et al. High Risk Use by Patients Prescribed Opioids for Pain and  its Role in Overdose Deaths. JAMA Intern Med 2014; 174: 796-801.
Recommendation Ten
When prescribing opioids for chronic pain, providers should use 
urine drug testing before starting opioid therapy and consider 
urine drug testing at least annually to assess for prescribed 
medications as well as other controlled prescription drugs and 
illicit drugs 
(Recommendation category: B, evidence type: 4) 
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Ten Rationale
 Urine drug tests can provide useful information about  
unreported drug use that can increase patients’ risk for 
overdose, such as benzodiazepines, or heroin
 Factors influencing category B designation:
• Cost burden for patients—not always covered by insurance
• Test results often misinterpreted by providers
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Eleven
Providers should avoid prescribing opioid pain medication for 
patients receiving benzodiazepines whenever possible. 
(Recommendation category: A, evidence type: 3)
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Eleven Rationale
 Concurrent benzodiazepine and opioid prescription associated 
with a near quadrupling of risk for overdose death compared 
with opioid prescription alone (case-cohort study)
 Concurrent benzodiazepine use found in large proportions of 
opioid-related overdose deaths in epidemiologic case series
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Twelve
Providers should offer or arrange evidence-based treatment 
(usually medication-assisted treatment with buprenorphine or 
methadone in combination with behavioral therapies) for 
patients with opioid use disorder. 
(Recommendation category: A, evidence type: 3)
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Recommendation Twelve Rationale
 Prevalence of opioid use disorder (previously called opioid 
dependence, or addiction) among primary care patients on 
chronic opioid therapy 3%-26%
 Buprenorphine or methadone effective in preventing relapse 
among patients with opioid use disorder
*findings summarized from the clinical and contextual evidence reviews
PRE-DECISIONAL; DRAFT; DOES NOT REPRESENT AGENCY DETERMINATION OR POLICY
Thank you
This information is distributed solely for the purpose of pre-
dissemination review. It has not been formally disseminated by 
the Centers for Disease Control and Prevention. It does not 
represent and should not be construed to represent any agency 
determination or policy.
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